Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment

Betsy Goodfellow | October 27, 2023 | News story | Medical Communications FDA, Opthalmology, Roche, Vabysmo, retinal vein occlusion 

Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) for the treatment of macular edema following retinal vein occlusion (RVO).

This approval marks the third indication for Vabysmo, following neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME). These three conditions combined affect approximately 70 million people globally and are among the leading causes of vision loss.

The drug is the first and only bispecific antibody to be approved for treatment of the eye. The approval in RVO follows positive information from the global phase 3 BALATON and COMINO studies which demonstrated an early and sustained improvement in vision in patients with branch and central RVO.

Advertisement

The drug was generally well tolerated, with a consistent safety profile and the most common adverse reaction being conjunctival haemorrhage.

Levi Garraway, MD PhD, Roche’s chief medical officer and head of Global Product Development, commented: “Vabysmo is a new treatment option for RVO that can help people preserve and improve their vision, with the added benefit of retinal drying. The efficacy and safety profile of Vabysmo has been well established in global clinical trials and is reinforced by a growing breadth of real-world evidence, with hundreds of thousands of people treated.”

Betsy Goodfellow

Related Content

brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631_1

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation

Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant

The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

The Gateway to Local Adoption Series

Latest content